ProteinQure Collaborates with AstraZeneca to Design Novel Peptide Therapeutics
ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of accelerating the research and development of peptide therapeutics.
Peptide therapeutics have unique properties that make them highly effective against some disease targets outside the scope of traditional small molecule and antibody modalities. However, due to the number of peptide variations, very few of these potential therapeutics have been studied. Integrating high-accuracy biophysical models and machine learning, it is possible to explore this vast therapeutic space and design peptide libraries with broad applicability in drug discovery.
The collaboration will leverage ProteinQure's expertise in computational methods and structure-based drug design. AstraZeneca will conduct experimental validation, drawing on the company’s extensive expertise in biologics.
"We are excited to collaborate with AstraZeneca to demonstrate the application of our technology on a large scale. By combining ProteinQure's proprietary computational tools with AstraZeneca’s ability to refine and validate millions of therapeutic candidates in high-throughput, we can rapidly determine therapeutic leads outside the scope of conventional synthetic antibody libraries. State-of-the-art computational tools have not been fully explored in biologics R&D and we are excited to partner with AstraZeneca with the aim of discovering novel therapeutic leads for some of the most challenging drug targets faced by the industry," said Chris Ing, CSO, ProteinQure.
"The combination of designed peptide libraries, based on ProteinQure’s computational methods, with our advanced capabilities in display technologies will help us harness the potential of this therapeutic class. AstraZeneca continues to collaborate with cutting-edge companies in our ambition to discover novel treatments and increase the speed at which we can bring treatments to patients," said Tristan Vaughan, Vice President Antibody Discovery & Protein Engineering, R&D, AstraZeneca.
About ProteinQure Inc.
ProteinQure is a computational drug discovery platform for protein-based pharmaceuticals. Their platform combines quantum computing, machine learning and molecular dynamics simulations to help refine and optimize protein therapeutics. These techniques are less reliant on data than other computational approaches and have the potential to explore new therapeutic space. ProteinQure collaborates with its partners to help design the drugs of tomorrow. ProteinQure is headquartered in Toronto, Canada. For more information please visit www.proteinqure.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PACIFIC-DRILLING31.10.2020 00:54:12 CET | Press release
Pacific Drilling Commences Voluntary Chapter 11 Proceedings; Restructuring Support Agreement to Eliminate All $1.1 Billion of Bond Debt; World-wide Operations Expected to Continue as Usual
CA-HOMESTEAD-CAPITAL31.10.2020 00:09:11 CET | Press release
Homestead Capital Closes Fund III at Target, Surpasses $1 Billion in Cumulative AUM
NY-HUNTER-POINT-CAPITAL30.10.2020 19:05:04 CET | Press release
Bennett Goodman and Avi Kalichstein Launch Hunter Point Capital to Invest in Alternative Investment Managers
PROCAD30.10.2020 17:33:11 CET | Press release
Code:n@xt: PROCAD to Lift the Veil on a New PLM Generation
CA-ANDERSEN-GLOBAL30.10.2020 14:55:04 CET | Pressemeddelelse
Andersen Global udvider sin dækning til Skt. Kitts og Nevis
NY-INX-LIMITED30.10.2020 14:02:12 CET | Press release
INX Applies for Listing on the Canadian Securities Exchange (CSE)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom